Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders
21 Maggio 2024 - 5:30PM
Pharming Group reports on results of the 2024 Annual General
Meeting of Shareholders
Leiden, the Netherlands, May 21,
2024: Pharming Group N.V. (“Pharming” or “the Company”)
(Euronext: PHARM/Nasdaq: PHAR) announces that at its Annual General
Meeting of Shareholders (AGM) held today, all proposals were
approved.The shareholders approved the proposals to reappoint Ms.
Barbara Yanni (agenda item 4.a) and Mr. Mark Pykett (agenda item
4.b), upon binding recommendation of the Board of Directors, as
Non-Executive Directors for a period of four years.
In addition, the proposals for the adoption of
the updated Remuneration Policy for members of the Board of
Directors (agenda item 3), the authorization for the Board of
Directors to issue shares and/or options (agenda item 5) and the
authorization for the Board of Directors to repurchase shares
(agenda item 6) were approved by the shareholders.
A recording of the webcast, presentation slides
from today’s AGM, and more details regarding agenda items are
available on the Company’s website in the Investor Relations
section.
About Pharming Group N.V.
Pharming Group N.V. (EURONEXT Amsterdam:
PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated
to transforming the lives of patients with rare, debilitating, and
life-threatening diseases. Pharming is commercializing and
developing an innovative portfolio of protein replacement therapies
and precision medicines, including small molecules and biologics
that are in clinical development. Pharming is headquartered in
Leiden, the Netherlands, and has employees around the globe who
serve patients in over 30 markets in North America, Europe, the
Middle East, Africa, and Asia-Pacific.
For more information, visit www.pharming.com and
find us on LinkedIn.
Inside Information
This press release relates to the disclosure of
information that qualifies, or may have qualified, as inside
information within the meaning of Article 7(1) of the EU Market
Abuse Regulation.
For further public information,
contact:
Pharming Group, Leiden, The NetherlandsMichael
Levitan, VP Investor Relations & Corporate CommunicationsT: +1
(908) 705 1696E: investor@pharming.com
FTI Consulting, London, UKVictoria Foster
Mitchell/Alex Shaw/Amy ByrneT: +44 203 727 1000
LifeSpring Life Sciences Communication, Amsterdam,
The NetherlandsLeon MelensT: +31 6 53 81 64 27E:
pharming@lifespring.nl
Grafico Azioni Pharming Group NV (TG:PHGN)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Pharming Group NV (TG:PHGN)
Storico
Da Dic 2023 a Dic 2024
